ESP block
PreclinicalSmall molecule
ESP block is one of 34 small molecule programs targeting Chronic pain. It is currently in Preclinical.
1
Indications
5
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Nucynta
CCollegium Pharmaceutical, Inc.
Phase 3
Tramadol Plus Acetaminophen
Johnson & JohnsonPhase 3
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
MS Contin
Merck & Co.Preclinical
Oravescent Fentanyl
CCephalon
Phase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Dayvigo
EisaiPreclinical
Ultram
Haisco Pharmaceutical Group Co., Ltd.Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic pain2 trials
Spinal Surgery1 trial
USG Guided ESP Block in Spinal Surgery
Completed·—·Phase 4·NCT04148729·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ESP block. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYonsei University